Cannaus
  • Home
  • State News
    • ACT
    • QLD
    • NSW
    • NT
    • SA
    • TAS
    • VIC
    • WA
  • Topics
    • Business
    • CBD
    • Government
    • Hemp
    • International
    • Legalisation
    • Medicinal Cannabis
    • Offences
    • Research
    • Misc
  • Cannabis Companies
No Result
View All Result
Cannaus

Neurotech International (ASX: NTI) finds cannabis strain can improve the efficacy of Prednisone

3 years ago
in National, Uncategorized
2
Close up of cannabis bud

Close up of cannabis bud

Share on FacebookShare on Twitter

On December 1st, Neurotech International (ASX: NTI) announced that its recent study found that a cannabis strain can reduce the negative side effects people often experience on Prednisone. 

Prednisone is a medication that belongs in the “Corticosteroids” class. It’s used to treat immune-inflammatory conditions like multiple sclerosis (MS) and rheumatoid arthritis, as well as autoimmune and neurological disorders. Prednisone carries many nasty side effects, including high blood sugar, increased risk of infection, glaucoma, cataracts, and osteoporosis. 

However, people taking Prednisone may not be stuck with these forever.

NTI has found that combining cannabis strain NTI164 with Prednisone allows people to get the anti-inflammatory benefits of Prednisone at a lower dose. Taking a lower dose will likely give people fewer side effects. 

While you can see the full list of results in NTI’s December 1st ASX announcement, NTI was able to reduce Prednisone’s dose “anywhere from 70% to 90%” by combining it with NTI164. To find this, the study compared Prednisone to a combination of NTI164 and Prednisone in human neuronal cells (cells of the nervous system and brain). 

According to Neurotech International Non-Executive Director, Professor Emeritus Allan Cripps, giving people lower doses of Prednisone could result in “better clinical outcomes.”

If this can be translated to human studies; better clinical outcomes with less side effects would be expected for the treatment of diseases associated (with) immune inflammation.

He also says the results of the study demonstrate the “applications of the ‘entourage effect’.” 

NTI164 was developed by Dolce Cann Global and is included in a patent filed by NTI. NTI is currently looking for strategic partners to commercialise NTI164. The company is also researching how NTI164 impacts two other anti-inflammatory drugs (Diclofenac and Celebrex).

The Corticosteroids market is currently valued at around $US5 billion (roughly $AU7 billion) has a CAGR of 4.3% — so NTI’s work with NTI164 could be very lucrative for the company if it hits the market. 

NTI164 is just one small part of NTI’s work, as the company is also researching and developing rare cannabis strains. They’ve currently licensed 80 unique strains. 

Tags: BusinessMedicinalResearch
Share25Tweet16
Karie Cornell

Karie Cornell

Based in Victoria, Karie's passionate about pro-cannabis legislation in Australia. She joined Cannaus to share and bring awareness to the latest cannabis news across Australia.

Related Posts

Cannabis leaf with seeds
National

WA government classifies a cannabis seed the same as a fully-grown plant

January 13, 2022
Small cannabis plant growing in a pot
National

New Zealand-based cannabis producer Greenfern reaches partnership agreement with Cannvalate

January 13, 2022
Cannabis medicine
National

Study shows the majority of women using medical cannabis for endometriosis obtain it illegally

January 11, 2022
Green cannabis leaf on wood
National

Cannim set to become major name in adult-use cannabis market through strategic merger

December 27, 2021
Cannabis oil with bud
National

Elixinol Wellness (ASX: EXL) signs deal with major British cannabis company

December 27, 2021
Penalty
National

TGA fines St Francis Pharmacy nearly $40k for advertising medicinal cannabis

December 23, 2021
Subscribe
Notify of
guest
guest
2 Comments
Inline Feedbacks
View all comments
Weekly Cannabis News

Get the latest Australian cannabis news straight to your inbox every week.

Enter your email address
  • Home
  • Contact
  • Privacy Policy

Disclaimer
Cannaus does not recommend that anyone uses cannabis for medical or adult use purposes unless consulted by a medical professional. Cannabis is a drug and may have negative side effects. Please consult with your doctor to find out if cannabis is right for you.

  • Home
  • State News
    • ACT
    • QLD
    • NSW
    • NT
    • SA
    • TAS
    • VIC
    • WA
  • Topics
    • Business
    • CBD
    • Government
    • Hemp
    • International
    • Legalisation
    • Medicinal Cannabis
    • Offences
    • Research
    • Misc
  • Cannabis Companies
No Result
View All Result
Weekly Cannabis News

Get the latest Australian cannabis news straight to your inbox every week.

Enter your email address

Thanks, I’m not interested

wpDiscuz